|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Autoimmune Nodopathy (CIDP-like) Evaluation
Test Code18702
CPT Codes
86255 (x4)<br><strong>This test is not available for New York patient testing</strong>
Includes
Neurofascin 155 Ab
Neurofascin 186 Ab
Contactin 1 Ab
CNTN1/CASPR1 Ab
Neurofascin 186 Ab
Contactin 1 Ab
CNTN1/CASPR1 Ab
Preferred Specimen
1 mL serum
Minimum Volume
0.5 mL
Instructions
Draw blood in either serum separator tube (SST) or red-top tube (no gel), centrifuge within 24 hours and transfer serum to a plastic transport tube.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 21 days
Refrigerated: 14 days
Frozen: 21 days
Methodology
Cell Based Assay
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Thurs, Sun; Report available: 6-11 days
Reference Range
| Neurofascin 155 Ab | Negative |
| Neurofascin 186 Ab | Negative |
| Contactin 1 Ab | Negative |
| CNTN1/CASPR1 Ab | Negative |
Clinical Significance
Chronic autoimmune peripheral neuropathies include a variety of disorders. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) defines a syndrome with chronic symmetrical proximal and distal muscle weakness and areflexia. Several subtypes have been recognized, depending on whether there is localization and/or predominance of motor or sensory symptoms. Previously considered a type of CIDP, patients in whom autoantibodies to components of the myelinated nerve node or paranode are present have been characterized as having a separate syndrome. It differs from CIDP in presentation (patients often have ataxia and tremor), pathogenesis (absence of significant inflammatory infiltrate suggest that antibodies have a direct effect), and response to treatment (unlike patients with CIDP, it is unlikely to respond to IVIg and may need alternative therapy, such as rituximab). The separate syndrome has been termed autoimmune nodopathy. Testing for the associated autoantibodies can help distinguish it for CIDP.
